/
Vivos Inc. (the Company, we, us, our ) is a radiation oncology medical device company engaged in the development of its yttrium-90 ( Y-90 ) based precision radionuclide therapy devices. This includes RadioGel Precision Radionuclide Therapy (Human Division) for treating solid tumors and positive surgical margins in humans and IsoPet (Animal Division) for treating solid tumors in animals.
The business is unprofitable at the operating level (-4628.68% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 1268.9% YoY with margins expanding 47511.1pp.
ROIC dropped from -117.16% to -127.49%, capital efficiency is deteriorating. Negative free cash flow of -$2M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$78K
▲ +1268.9% YoY
Net Income (TTM)
-$3M
▼ -5.3% YoY
Op. Margin
-3664.15%
▲ +47511.1pp YoY
ROIC
-95.27%
▼ -10.3pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$2M
Op. Cash Flow (TTM)
-$2M
▼ -22.2% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$3M
5Y CAGR: +57.7%
Continue Research